nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—CYP2D6—Temsirolimus—kidney cancer	0.138	0.372	CbGbCtD
Methylphenidate—CYP2D6—Pazopanib—kidney cancer	0.0724	0.195	CbGbCtD
Methylphenidate—CYP2D6—Erlotinib—kidney cancer	0.0517	0.139	CbGbCtD
Methylphenidate—CYP2D6—Sorafenib—kidney cancer	0.042	0.113	CbGbCtD
Methylphenidate—CYP2D6—Vinblastine—kidney cancer	0.0415	0.112	CbGbCtD
Methylphenidate—CYP2D6—Doxorubicin—kidney cancer	0.0255	0.0687	CbGbCtD
Methylphenidate—Cyclopentolate—BCHE—kidney cancer	0.00113	1	CrCbGaD
Methylphenidate—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—ACHE—kidney cancer	0.000641	0.0737	CbGpPWpGaD
Methylphenidate—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—kidney cancer	0.000558	0.0642	CbGpPWpGaD
Methylphenidate—SLC6A3—Dopaminergic Neurogenesis—ALDH1A1—kidney cancer	0.000379	0.0435	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—LRRK2—kidney cancer	0.000329	0.0378	CbGpPWpGaD
Methylphenidate—CYP2D6—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.000293	0.0337	CbGpPWpGaD
Methylphenidate—SLC6A4—Monoamine Transport—ACHE—kidney cancer	0.000277	0.0319	CbGpPWpGaD
Methylphenidate—SLC6A2—Monoamine Transport—ACHE—kidney cancer	0.000239	0.0274	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—CASP2—kidney cancer	0.000238	0.0273	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—APAF1—kidney cancer	0.000223	0.0257	CbGpPWpGaD
Methylphenidate—SLC6A3—Monoamine Transport—ACHE—kidney cancer	0.000211	0.0243	CbGpPWpGaD
Methylphenidate—Constipation—Gemcitabine—kidney cancer	0.000203	0.000328	CcSEcCtD
Methylphenidate—Nausea—Erlotinib—kidney cancer	0.000203	0.000328	CcSEcCtD
Methylphenidate—Alopecia—Capecitabine—kidney cancer	0.000203	0.000327	CcSEcCtD
Methylphenidate—Dry mouth—Paclitaxel—kidney cancer	0.000203	0.000327	CcSEcCtD
Methylphenidate—Mood swings—Doxorubicin—kidney cancer	0.000203	0.000327	CcSEcCtD
Methylphenidate—Diarrhoea—Sunitinib—kidney cancer	0.000202	0.000327	CcSEcCtD
Methylphenidate—Mental disorder—Capecitabine—kidney cancer	0.000201	0.000325	CcSEcCtD
Methylphenidate—Asthenia—Dactinomycin—kidney cancer	0.000201	0.000324	CcSEcCtD
Methylphenidate—Confusional state—Paclitaxel—kidney cancer	0.0002	0.000323	CcSEcCtD
Methylphenidate—Malnutrition—Capecitabine—kidney cancer	0.0002	0.000323	CcSEcCtD
Methylphenidate—Erythema—Capecitabine—kidney cancer	0.0002	0.000323	CcSEcCtD
Methylphenidate—Dehydration—Doxorubicin—kidney cancer	0.000199	0.000321	CcSEcCtD
Methylphenidate—Anaphylactic shock—Paclitaxel—kidney cancer	0.000199	0.000321	CcSEcCtD
Methylphenidate—Oedema—Paclitaxel—kidney cancer	0.000199	0.000321	CcSEcCtD
Methylphenidate—Abdominal pain—Vincristine—kidney cancer	0.000198	0.000319	CcSEcCtD
Methylphenidate—Body temperature increased—Vincristine—kidney cancer	0.000198	0.000319	CcSEcCtD
Methylphenidate—Liver function test abnormal—Doxorubicin—kidney cancer	0.000197	0.000319	CcSEcCtD
Methylphenidate—Infection—Paclitaxel—kidney cancer	0.000197	0.000319	CcSEcCtD
Methylphenidate—CYP2D6—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.000197	0.0226	CbGpPWpGaD
Methylphenidate—Dizziness—Sunitinib—kidney cancer	0.000196	0.000316	CcSEcCtD
Methylphenidate—Feeling abnormal—Gemcitabine—kidney cancer	0.000196	0.000316	CcSEcCtD
Methylphenidate—Shock—Paclitaxel—kidney cancer	0.000195	0.000316	CcSEcCtD
Methylphenidate—Vomiting—Sorafenib—kidney cancer	0.000195	0.000315	CcSEcCtD
Methylphenidate—Abdominal pain upper—Doxorubicin—kidney cancer	0.000195	0.000315	CcSEcCtD
Methylphenidate—Nervous system disorder—Paclitaxel—kidney cancer	0.000195	0.000315	CcSEcCtD
Methylphenidate—Thrombocytopenia—Paclitaxel—kidney cancer	0.000194	0.000314	CcSEcCtD
Methylphenidate—Tachycardia—Paclitaxel—kidney cancer	0.000194	0.000313	CcSEcCtD
Methylphenidate—Rash—Sorafenib—kidney cancer	0.000194	0.000313	CcSEcCtD
Methylphenidate—Dermatitis—Sorafenib—kidney cancer	0.000194	0.000313	CcSEcCtD
Methylphenidate—Back pain—Capecitabine—kidney cancer	0.000193	0.000312	CcSEcCtD
Methylphenidate—Breast disorder—Doxorubicin—kidney cancer	0.000193	0.000312	CcSEcCtD
Methylphenidate—Skin disorder—Paclitaxel—kidney cancer	0.000193	0.000312	CcSEcCtD
Methylphenidate—Headache—Sorafenib—kidney cancer	0.000192	0.000311	CcSEcCtD
Methylphenidate—Muscle spasms—Capecitabine—kidney cancer	0.000192	0.00031	CcSEcCtD
Methylphenidate—Hyperhidrosis—Paclitaxel—kidney cancer	0.000192	0.00031	CcSEcCtD
Methylphenidate—Diarrhoea—Dactinomycin—kidney cancer	0.000192	0.000309	CcSEcCtD
Methylphenidate—Nasopharyngitis—Doxorubicin—kidney cancer	0.000191	0.000309	CcSEcCtD
Methylphenidate—Anorexia—Paclitaxel—kidney cancer	0.000189	0.000306	CcSEcCtD
Methylphenidate—Gastritis—Doxorubicin—kidney cancer	0.000189	0.000306	CcSEcCtD
Methylphenidate—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.000189	0.000304	CcSEcCtD
Methylphenidate—Vision blurred—Capecitabine—kidney cancer	0.000188	0.000304	CcSEcCtD
Methylphenidate—Vomiting—Sunitinib—kidney cancer	0.000188	0.000304	CcSEcCtD
Methylphenidate—Body temperature increased—Gemcitabine—kidney cancer	0.000188	0.000303	CcSEcCtD
Methylphenidate—Tremor—Capecitabine—kidney cancer	0.000187	0.000302	CcSEcCtD
Methylphenidate—Rash—Sunitinib—kidney cancer	0.000186	0.000301	CcSEcCtD
Methylphenidate—Dermatitis—Sunitinib—kidney cancer	0.000186	0.000301	CcSEcCtD
Methylphenidate—Ill-defined disorder—Capecitabine—kidney cancer	0.000185	0.000299	CcSEcCtD
Methylphenidate—Headache—Sunitinib—kidney cancer	0.000185	0.000299	CcSEcCtD
Methylphenidate—Asthma—Doxorubicin—kidney cancer	0.000185	0.000298	CcSEcCtD
Methylphenidate—Influenza—Doxorubicin—kidney cancer	0.000185	0.000298	CcSEcCtD
Methylphenidate—Anaemia—Capecitabine—kidney cancer	0.000185	0.000298	CcSEcCtD
Methylphenidate—Hypersensitivity—Vincristine—kidney cancer	0.000184	0.000298	CcSEcCtD
Methylphenidate—Nausea—Sorafenib—kidney cancer	0.000183	0.000295	CcSEcCtD
Methylphenidate—Pancreatitis—Doxorubicin—kidney cancer	0.000181	0.000293	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000181	0.000292	CcSEcCtD
Methylphenidate—Malaise—Capecitabine—kidney cancer	0.00018	0.000291	CcSEcCtD
Methylphenidate—Angina pectoris—Doxorubicin—kidney cancer	0.00018	0.000291	CcSEcCtD
Methylphenidate—Insomnia—Paclitaxel—kidney cancer	0.00018	0.00029	CcSEcCtD
Methylphenidate—Vertigo—Capecitabine—kidney cancer	0.000179	0.00029	CcSEcCtD
Methylphenidate—Asthenia—Vincristine—kidney cancer	0.000179	0.00029	CcSEcCtD
Methylphenidate—Syncope—Capecitabine—kidney cancer	0.000179	0.000289	CcSEcCtD
Methylphenidate—Leukopenia—Capecitabine—kidney cancer	0.000179	0.000289	CcSEcCtD
Methylphenidate—Paraesthesia—Paclitaxel—kidney cancer	0.000178	0.000288	CcSEcCtD
Methylphenidate—Vomiting—Dactinomycin—kidney cancer	0.000178	0.000287	CcSEcCtD
Methylphenidate—Bronchitis—Doxorubicin—kidney cancer	0.000178	0.000287	CcSEcCtD
Methylphenidate—Dyspnoea—Paclitaxel—kidney cancer	0.000177	0.000286	CcSEcCtD
Methylphenidate—Somnolence—Paclitaxel—kidney cancer	0.000177	0.000285	CcSEcCtD
Methylphenidate—Palpitations—Capecitabine—kidney cancer	0.000177	0.000285	CcSEcCtD
Methylphenidate—Rash—Dactinomycin—kidney cancer	0.000176	0.000285	CcSEcCtD
Methylphenidate—Nausea—Sunitinib—kidney cancer	0.000176	0.000284	CcSEcCtD
Methylphenidate—Loss of consciousness—Capecitabine—kidney cancer	0.000176	0.000283	CcSEcCtD
Methylphenidate—Pancytopenia—Doxorubicin—kidney cancer	0.000175	0.000283	CcSEcCtD
Methylphenidate—Dyspepsia—Paclitaxel—kidney cancer	0.000175	0.000282	CcSEcCtD
Methylphenidate—Cough—Capecitabine—kidney cancer	0.000174	0.000281	CcSEcCtD
Methylphenidate—Decreased appetite—Paclitaxel—kidney cancer	0.000173	0.000279	CcSEcCtD
Methylphenidate—Hypertension—Capecitabine—kidney cancer	0.000172	0.000278	CcSEcCtD
Methylphenidate—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000172	0.000277	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000171	0.000277	CcSEcCtD
Methylphenidate—Fatigue—Paclitaxel—kidney cancer	0.000171	0.000277	CcSEcCtD
Methylphenidate—Diarrhoea—Vincristine—kidney cancer	0.000171	0.000276	CcSEcCtD
Methylphenidate—Asthenia—Gemcitabine—kidney cancer	0.00017	0.000275	CcSEcCtD
Methylphenidate—Arthralgia—Capecitabine—kidney cancer	0.00017	0.000275	CcSEcCtD
Methylphenidate—Chest pain—Capecitabine—kidney cancer	0.00017	0.000275	CcSEcCtD
Methylphenidate—Myalgia—Capecitabine—kidney cancer	0.00017	0.000275	CcSEcCtD
Methylphenidate—Constipation—Paclitaxel—kidney cancer	0.00017	0.000274	CcSEcCtD
Methylphenidate—Pain—Paclitaxel—kidney cancer	0.00017	0.000274	CcSEcCtD
Methylphenidate—Anxiety—Capecitabine—kidney cancer	0.000169	0.000274	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000169	0.000273	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000169	0.000272	CcSEcCtD
Methylphenidate—Weight increased—Doxorubicin—kidney cancer	0.000168	0.000272	CcSEcCtD
Methylphenidate—Discomfort—Capecitabine—kidney cancer	0.000168	0.000271	CcSEcCtD
Methylphenidate—Pruritus—Gemcitabine—kidney cancer	0.000168	0.000271	CcSEcCtD
Methylphenidate—Weight decreased—Doxorubicin—kidney cancer	0.000167	0.00027	CcSEcCtD
Methylphenidate—Dry mouth—Capecitabine—kidney cancer	0.000166	0.000269	CcSEcCtD
Methylphenidate—Nausea—Dactinomycin—kidney cancer	0.000166	0.000268	CcSEcCtD
Methylphenidate—Pneumonia—Doxorubicin—kidney cancer	0.000166	0.000268	CcSEcCtD
Methylphenidate—Dizziness—Vincristine—kidney cancer	0.000165	0.000267	CcSEcCtD
Methylphenidate—Drowsiness—Doxorubicin—kidney cancer	0.000165	0.000266	CcSEcCtD
Methylphenidate—Infestation NOS—Doxorubicin—kidney cancer	0.000165	0.000266	CcSEcCtD
Methylphenidate—Infestation—Doxorubicin—kidney cancer	0.000165	0.000266	CcSEcCtD
Methylphenidate—Confusional state—Capecitabine—kidney cancer	0.000164	0.000265	CcSEcCtD
Methylphenidate—Feeling abnormal—Paclitaxel—kidney cancer	0.000164	0.000264	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000163	0.000264	CcSEcCtD
Methylphenidate—Oedema—Capecitabine—kidney cancer	0.000163	0.000263	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000162	0.000262	CcSEcCtD
Methylphenidate—Diarrhoea—Gemcitabine—kidney cancer	0.000162	0.000262	CcSEcCtD
Methylphenidate—Infection—Capecitabine—kidney cancer	0.000162	0.000261	CcSEcCtD
Methylphenidate—Shock—Capecitabine—kidney cancer	0.00016	0.000259	CcSEcCtD
Methylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A3—kidney cancer	0.00016	0.0184	CbGpPWpGaD
Methylphenidate—Conjunctivitis—Doxorubicin—kidney cancer	0.00016	0.000259	CcSEcCtD
Methylphenidate—Nervous system disorder—Capecitabine—kidney cancer	0.00016	0.000258	CcSEcCtD
Methylphenidate—Thrombocytopenia—Capecitabine—kidney cancer	0.00016	0.000258	CcSEcCtD
Methylphenidate—Tachycardia—Capecitabine—kidney cancer	0.000159	0.000257	CcSEcCtD
Methylphenidate—Vomiting—Vincristine—kidney cancer	0.000159	0.000257	CcSEcCtD
Methylphenidate—Skin disorder—Capecitabine—kidney cancer	0.000158	0.000256	CcSEcCtD
Methylphenidate—Sweating—Doxorubicin—kidney cancer	0.000158	0.000255	CcSEcCtD
Methylphenidate—Urticaria—Paclitaxel—kidney cancer	0.000158	0.000255	CcSEcCtD
Methylphenidate—Rash—Vincristine—kidney cancer	0.000158	0.000255	CcSEcCtD
Methylphenidate—Hyperhidrosis—Capecitabine—kidney cancer	0.000158	0.000254	CcSEcCtD
Methylphenidate—Dermatitis—Vincristine—kidney cancer	0.000158	0.000254	CcSEcCtD
Methylphenidate—Haematuria—Doxorubicin—kidney cancer	0.000157	0.000254	CcSEcCtD
Methylphenidate—Body temperature increased—Paclitaxel—kidney cancer	0.000157	0.000254	CcSEcCtD
Methylphenidate—Abdominal pain—Paclitaxel—kidney cancer	0.000157	0.000254	CcSEcCtD
Methylphenidate—Headache—Vincristine—kidney cancer	0.000157	0.000253	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000156	0.000252	CcSEcCtD
Methylphenidate—Epistaxis—Doxorubicin—kidney cancer	0.000155	0.000251	CcSEcCtD
Methylphenidate—Anorexia—Capecitabine—kidney cancer	0.000155	0.000251	CcSEcCtD
Methylphenidate—Sinusitis—Doxorubicin—kidney cancer	0.000155	0.00025	CcSEcCtD
Methylphenidate—Vomiting—Gemcitabine—kidney cancer	0.000151	0.000244	CcSEcCtD
Methylphenidate—Bradycardia—Doxorubicin—kidney cancer	0.000151	0.000243	CcSEcCtD
Methylphenidate—Rash—Gemcitabine—kidney cancer	0.00015	0.000242	CcSEcCtD
Methylphenidate—Dermatitis—Gemcitabine—kidney cancer	0.000149	0.000241	CcSEcCtD
Methylphenidate—Haemoglobin—Doxorubicin—kidney cancer	0.000149	0.00024	CcSEcCtD
Methylphenidate—Headache—Gemcitabine—kidney cancer	0.000149	0.00024	CcSEcCtD
Methylphenidate—SLC6A4—Monoamine Transport—TSC2—kidney cancer	0.000149	0.0171	CbGpPWpGaD
Methylphenidate—Nausea—Vincristine—kidney cancer	0.000149	0.00024	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000149	0.00024	CcSEcCtD
Methylphenidate—Rhinitis—Doxorubicin—kidney cancer	0.000148	0.000239	CcSEcCtD
Methylphenidate—Haemorrhage—Doxorubicin—kidney cancer	0.000148	0.000239	CcSEcCtD
Methylphenidate—Insomnia—Capecitabine—kidney cancer	0.000147	0.000238	CcSEcCtD
Methylphenidate—Pharyngitis—Doxorubicin—kidney cancer	0.000147	0.000237	CcSEcCtD
Methylphenidate—Paraesthesia—Capecitabine—kidney cancer	0.000146	0.000236	CcSEcCtD
Methylphenidate—Hypersensitivity—Paclitaxel—kidney cancer	0.000146	0.000236	CcSEcCtD
Methylphenidate—Urinary tract disorder—Doxorubicin—kidney cancer	0.000146	0.000236	CcSEcCtD
Methylphenidate—Connective tissue disorder—Doxorubicin—kidney cancer	0.000145	0.000235	CcSEcCtD
Methylphenidate—Dyspnoea—Capecitabine—kidney cancer	0.000145	0.000235	CcSEcCtD
Methylphenidate—Urethral disorder—Doxorubicin—kidney cancer	0.000145	0.000234	CcSEcCtD
Methylphenidate—Dyspepsia—Capecitabine—kidney cancer	0.000143	0.000232	CcSEcCtD
Methylphenidate—Visual impairment—Doxorubicin—kidney cancer	0.000143	0.00023	CcSEcCtD
Methylphenidate—Asthenia—Paclitaxel—kidney cancer	0.000143	0.00023	CcSEcCtD
Methylphenidate—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A3—kidney cancer	0.000142	0.0163	CbGpPWpGaD
Methylphenidate—Decreased appetite—Capecitabine—kidney cancer	0.000142	0.000229	CcSEcCtD
Methylphenidate—Nausea—Gemcitabine—kidney cancer	0.000141	0.000228	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000141	0.000227	CcSEcCtD
Methylphenidate—Fatigue—Capecitabine—kidney cancer	0.000141	0.000227	CcSEcCtD
Methylphenidate—Pruritus—Paclitaxel—kidney cancer	0.000141	0.000227	CcSEcCtD
Methylphenidate—Erythema multiforme—Doxorubicin—kidney cancer	0.00014	0.000226	CcSEcCtD
Methylphenidate—Pain—Capecitabine—kidney cancer	0.000139	0.000225	CcSEcCtD
Methylphenidate—Constipation—Capecitabine—kidney cancer	0.000139	0.000225	CcSEcCtD
Methylphenidate—Eye disorder—Doxorubicin—kidney cancer	0.000138	0.000223	CcSEcCtD
Methylphenidate—Flushing—Doxorubicin—kidney cancer	0.000137	0.000222	CcSEcCtD
Methylphenidate—Cardiac disorder—Doxorubicin—kidney cancer	0.000137	0.000222	CcSEcCtD
Methylphenidate—Diarrhoea—Paclitaxel—kidney cancer	0.000136	0.000219	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—SLC5A3—kidney cancer	0.000134	0.0154	CbGpPWpGaD
Methylphenidate—Feeling abnormal—Capecitabine—kidney cancer	0.000134	0.000217	CcSEcCtD
Methylphenidate—Angiopathy—Doxorubicin—kidney cancer	0.000134	0.000217	CcSEcCtD
Methylphenidate—Immune system disorder—Doxorubicin—kidney cancer	0.000134	0.000216	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Capecitabine—kidney cancer	0.000133	0.000215	CcSEcCtD
Methylphenidate—Mediastinal disorder—Doxorubicin—kidney cancer	0.000133	0.000215	CcSEcCtD
Methylphenidate—Chills—Doxorubicin—kidney cancer	0.000133	0.000214	CcSEcCtD
Methylphenidate—Arrhythmia—Doxorubicin—kidney cancer	0.000132	0.000213	CcSEcCtD
Methylphenidate—Dizziness—Paclitaxel—kidney cancer	0.000131	0.000212	CcSEcCtD
Methylphenidate—Alopecia—Doxorubicin—kidney cancer	0.000131	0.000211	CcSEcCtD
Methylphenidate—Mental disorder—Doxorubicin—kidney cancer	0.00013	0.000209	CcSEcCtD
Methylphenidate—Urticaria—Capecitabine—kidney cancer	0.000129	0.000209	CcSEcCtD
Methylphenidate—Body temperature increased—Capecitabine—kidney cancer	0.000129	0.000208	CcSEcCtD
Methylphenidate—Abdominal pain—Capecitabine—kidney cancer	0.000129	0.000208	CcSEcCtD
Methylphenidate—Malnutrition—Doxorubicin—kidney cancer	0.000129	0.000208	CcSEcCtD
Methylphenidate—Erythema—Doxorubicin—kidney cancer	0.000129	0.000208	CcSEcCtD
Methylphenidate—SLC6A2—Monoamine Transport—TSC2—kidney cancer	0.000128	0.0147	CbGpPWpGaD
Methylphenidate—Tension—Doxorubicin—kidney cancer	0.000126	0.000204	CcSEcCtD
Methylphenidate—Vomiting—Paclitaxel—kidney cancer	0.000126	0.000204	CcSEcCtD
Methylphenidate—Rash—Paclitaxel—kidney cancer	0.000125	0.000202	CcSEcCtD
Methylphenidate—Dermatitis—Paclitaxel—kidney cancer	0.000125	0.000202	CcSEcCtD
Methylphenidate—Nervousness—Doxorubicin—kidney cancer	0.000125	0.000202	CcSEcCtD
Methylphenidate—Back pain—Doxorubicin—kidney cancer	0.000125	0.000201	CcSEcCtD
Methylphenidate—Headache—Paclitaxel—kidney cancer	0.000124	0.000201	CcSEcCtD
Methylphenidate—Muscle spasms—Doxorubicin—kidney cancer	0.000124	0.0002	CcSEcCtD
Methylphenidate—Vision blurred—Doxorubicin—kidney cancer	0.000121	0.000196	CcSEcCtD
Methylphenidate—Hypersensitivity—Capecitabine—kidney cancer	0.00012	0.000194	CcSEcCtD
Methylphenidate—Ill-defined disorder—Doxorubicin—kidney cancer	0.000119	0.000193	CcSEcCtD
Methylphenidate—Anaemia—Doxorubicin—kidney cancer	0.000119	0.000192	CcSEcCtD
Methylphenidate—Agitation—Doxorubicin—kidney cancer	0.000118	0.000191	CcSEcCtD
Methylphenidate—Nausea—Paclitaxel—kidney cancer	0.000118	0.000191	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—KEAP1—kidney cancer	0.000117	0.0135	CbGpPWpGaD
Methylphenidate—Asthenia—Capecitabine—kidney cancer	0.000117	0.000189	CcSEcCtD
Methylphenidate—Malaise—Doxorubicin—kidney cancer	0.000116	0.000187	CcSEcCtD
Methylphenidate—Vertigo—Doxorubicin—kidney cancer	0.000116	0.000187	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—SLC5A3—kidney cancer	0.000116	0.0133	CbGpPWpGaD
Methylphenidate—Syncope—Doxorubicin—kidney cancer	0.000115	0.000186	CcSEcCtD
Methylphenidate—Pruritus—Capecitabine—kidney cancer	0.000115	0.000186	CcSEcCtD
Methylphenidate—Leukopenia—Doxorubicin—kidney cancer	0.000115	0.000186	CcSEcCtD
Methylphenidate—Palpitations—Doxorubicin—kidney cancer	0.000114	0.000184	CcSEcCtD
Methylphenidate—SLC6A3—Monoamine Transport—TSC2—kidney cancer	0.000113	0.013	CbGpPWpGaD
Methylphenidate—Loss of consciousness—Doxorubicin—kidney cancer	0.000113	0.000183	CcSEcCtD
Methylphenidate—Cough—Doxorubicin—kidney cancer	0.000112	0.000181	CcSEcCtD
Methylphenidate—Convulsion—Doxorubicin—kidney cancer	0.000112	0.00018	CcSEcCtD
Methylphenidate—Diarrhoea—Capecitabine—kidney cancer	0.000112	0.00018	CcSEcCtD
Methylphenidate—Hypertension—Doxorubicin—kidney cancer	0.000111	0.000179	CcSEcCtD
Methylphenidate—Myalgia—Doxorubicin—kidney cancer	0.00011	0.000177	CcSEcCtD
Methylphenidate—Arthralgia—Doxorubicin—kidney cancer	0.00011	0.000177	CcSEcCtD
Methylphenidate—Chest pain—Doxorubicin—kidney cancer	0.00011	0.000177	CcSEcCtD
Methylphenidate—Anxiety—Doxorubicin—kidney cancer	0.000109	0.000176	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000109	0.000176	CcSEcCtD
Methylphenidate—Discomfort—Doxorubicin—kidney cancer	0.000108	0.000175	CcSEcCtD
Methylphenidate—Dizziness—Capecitabine—kidney cancer	0.000108	0.000174	CcSEcCtD
Methylphenidate—Dry mouth—Doxorubicin—kidney cancer	0.000107	0.000173	CcSEcCtD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—ACHE—kidney cancer	0.000107	0.0123	CbGpPWpGaD
Methylphenidate—Confusional state—Doxorubicin—kidney cancer	0.000106	0.000171	CcSEcCtD
Methylphenidate—Anaphylactic shock—Doxorubicin—kidney cancer	0.000105	0.00017	CcSEcCtD
Methylphenidate—Oedema—Doxorubicin—kidney cancer	0.000105	0.00017	CcSEcCtD
Methylphenidate—Infection—Doxorubicin—kidney cancer	0.000104	0.000169	CcSEcCtD
Methylphenidate—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	0.000104	0.012	CbGpPWpGaD
Methylphenidate—Vomiting—Capecitabine—kidney cancer	0.000104	0.000167	CcSEcCtD
Methylphenidate—Shock—Doxorubicin—kidney cancer	0.000103	0.000167	CcSEcCtD
Methylphenidate—Nervous system disorder—Doxorubicin—kidney cancer	0.000103	0.000166	CcSEcCtD
Methylphenidate—Thrombocytopenia—Doxorubicin—kidney cancer	0.000103	0.000166	CcSEcCtD
Methylphenidate—Rash—Capecitabine—kidney cancer	0.000103	0.000166	CcSEcCtD
Methylphenidate—Dermatitis—Capecitabine—kidney cancer	0.000103	0.000166	CcSEcCtD
Methylphenidate—Tachycardia—Doxorubicin—kidney cancer	0.000103	0.000166	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—SLC5A3—kidney cancer	0.000102	0.0118	CbGpPWpGaD
Methylphenidate—Headache—Capecitabine—kidney cancer	0.000102	0.000165	CcSEcCtD
Methylphenidate—Skin disorder—Doxorubicin—kidney cancer	0.000102	0.000165	CcSEcCtD
Methylphenidate—Hyperhidrosis—Doxorubicin—kidney cancer	0.000102	0.000164	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—KEAP1—kidney cancer	0.000101	0.0116	CbGpPWpGaD
Methylphenidate—Anorexia—Doxorubicin—kidney cancer	0.0001	0.000162	CcSEcCtD
Methylphenidate—Nausea—Capecitabine—kidney cancer	9.68e-05	0.000156	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Doxorubicin—kidney cancer	9.57e-05	0.000155	CcSEcCtD
Methylphenidate—Insomnia—Doxorubicin—kidney cancer	9.5e-05	0.000153	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HSPD1—kidney cancer	9.47e-05	0.0109	CbGpPWpGaD
Methylphenidate—Paraesthesia—Doxorubicin—kidney cancer	9.43e-05	0.000152	CcSEcCtD
Methylphenidate—Dyspnoea—Doxorubicin—kidney cancer	9.37e-05	0.000151	CcSEcCtD
Methylphenidate—Somnolence—Doxorubicin—kidney cancer	9.34e-05	0.000151	CcSEcCtD
Methylphenidate—Dyspepsia—Doxorubicin—kidney cancer	9.25e-05	0.000149	CcSEcCtD
Methylphenidate—Decreased appetite—Doxorubicin—kidney cancer	9.13e-05	0.000147	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Doxorubicin—kidney cancer	9.07e-05	0.000146	CcSEcCtD
Methylphenidate—Fatigue—Doxorubicin—kidney cancer	9.06e-05	0.000146	CcSEcCtD
Methylphenidate—Constipation—Doxorubicin—kidney cancer	8.99e-05	0.000145	CcSEcCtD
Methylphenidate—Pain—Doxorubicin—kidney cancer	8.99e-05	0.000145	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—KEAP1—kidney cancer	8.95e-05	0.0103	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—HNF1B—kidney cancer	8.85e-05	0.0102	CbGpPWpGaD
Methylphenidate—CYP2D6—Xenobiotics—CYP1A1—kidney cancer	8.71e-05	0.01	CbGpPWpGaD
Methylphenidate—Feeling abnormal—Doxorubicin—kidney cancer	8.66e-05	0.00014	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—KCNMA1—kidney cancer	8.62e-05	0.00991	CbGpPWpGaD
Methylphenidate—Gastrointestinal pain—Doxorubicin—kidney cancer	8.59e-05	0.000139	CcSEcCtD
Methylphenidate—CYP2D6—Tamoxifen metabolism—CYP1A1—kidney cancer	8.37e-05	0.00963	CbGpPWpGaD
Methylphenidate—Urticaria—Doxorubicin—kidney cancer	8.35e-05	0.000135	CcSEcCtD
Methylphenidate—Body temperature increased—Doxorubicin—kidney cancer	8.31e-05	0.000134	CcSEcCtD
Methylphenidate—Abdominal pain—Doxorubicin—kidney cancer	8.31e-05	0.000134	CcSEcCtD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	8.26e-05	0.0095	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—ACY1—kidney cancer	8.01e-05	0.00921	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL13—kidney cancer	7.95e-05	0.00914	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Doxorubicin—kidney cancer	7.74e-05	0.000125	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—JUND—kidney cancer	7.73e-05	0.00889	CbGpPWpGaD
Methylphenidate—Asthenia—Doxorubicin—kidney cancer	7.54e-05	0.000122	CcSEcCtD
Methylphenidate—Pruritus—Doxorubicin—kidney cancer	7.43e-05	0.00012	CcSEcCtD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	7.28e-05	0.00837	CbGpPWpGaD
Methylphenidate—Diarrhoea—Doxorubicin—kidney cancer	7.19e-05	0.000116	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—SLC5A5—kidney cancer	7.09e-05	0.00815	CbGpPWpGaD
Methylphenidate—Dizziness—Doxorubicin—kidney cancer	6.95e-05	0.000112	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—SLC2A1—kidney cancer	6.85e-05	0.00787	CbGpPWpGaD
Methylphenidate—Vomiting—Doxorubicin—kidney cancer	6.68e-05	0.000108	CcSEcCtD
Methylphenidate—Rash—Doxorubicin—kidney cancer	6.63e-05	0.000107	CcSEcCtD
Methylphenidate—Dermatitis—Doxorubicin—kidney cancer	6.62e-05	0.000107	CcSEcCtD
Methylphenidate—Headache—Doxorubicin—kidney cancer	6.58e-05	0.000106	CcSEcCtD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—CYP1A1—kidney cancer	6.47e-05	0.00743	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	6.45e-05	0.00742	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—RYR1—kidney cancer	6.44e-05	0.00741	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—EGR1—kidney cancer	6.36e-05	0.00731	CbGpPWpGaD
Methylphenidate—Nausea—Doxorubicin—kidney cancer	6.24e-05	0.000101	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—SLC5A5—kidney cancer	6.1e-05	0.00701	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—EGR1—kidney cancer	6.03e-05	0.00693	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—SLC2A1—kidney cancer	5.89e-05	0.00677	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTP1—kidney cancer	5.71e-05	0.00656	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—RYR1—kidney cancer	5.71e-05	0.00656	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—EGR1—kidney cancer	5.47e-05	0.00628	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—SLC5A5—kidney cancer	5.4e-05	0.00621	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTM1—kidney cancer	5.25e-05	0.00603	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—SLC2A1—kidney cancer	5.22e-05	0.006	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—KCNMA1—kidney cancer	5.05e-05	0.00581	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—EGR1—kidney cancer	4.92e-05	0.00566	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTP1—kidney cancer	4.91e-05	0.00564	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—ACHE—kidney cancer	4.88e-05	0.00561	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—EGR1—kidney cancer	4.84e-05	0.00557	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	4.55e-05	0.00523	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTM1—kidney cancer	4.51e-05	0.00519	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—ALDH1A1—kidney cancer	4.39e-05	0.00504	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTP1—kidney cancer	4.35e-05	0.005	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—BCHE—kidney cancer	4.25e-05	0.00489	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HIF1A—kidney cancer	4.19e-05	0.00482	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTM1—kidney cancer	4e-05	0.00459	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	3.84e-05	0.00442	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—ACHE—kidney cancer	3.74e-05	0.0043	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	3.71e-05	0.00427	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ATP7B—kidney cancer	3.7e-05	0.00425	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC5A3—kidney cancer	3.7e-05	0.00425	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ANXA2—kidney cancer	3.7e-05	0.00425	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	3.62e-05	0.00416	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	3.57e-05	0.0041	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	3.4e-05	0.00391	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	3.29e-05	0.00378	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ANXA2—kidney cancer	3.28e-05	0.00377	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC5A3—kidney cancer	3.28e-05	0.00377	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ATP7B—kidney cancer	3.28e-05	0.00377	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—BCHE—kidney cancer	3.26e-05	0.00374	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	2.93e-05	0.00337	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	2.7e-05	0.0031	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTT1—kidney cancer	2.58e-05	0.00296	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—JUN—kidney cancer	2.53e-05	0.00291	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—kidney cancer	2.51e-05	0.00289	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—PTGS1—kidney cancer	2.42e-05	0.00278	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—VEGFA—kidney cancer	2.21e-05	0.00254	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—POMC—kidney cancer	2.19e-05	0.00251	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—BRAF—kidney cancer	2.17e-05	0.00249	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—JUN—kidney cancer	2.07e-05	0.00237	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PTEN—kidney cancer	2e-05	0.0023	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.95e-05	0.00224	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.89e-05	0.00217	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—RAF1—kidney cancer	1.81e-05	0.00208	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTP1—kidney cancer	1.79e-05	0.00205	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTP1—kidney cancer	1.76e-05	0.00203	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.73e-05	0.00199	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.67e-05	0.00192	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—BRAF—kidney cancer	1.66e-05	0.00191	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTM1—kidney cancer	1.64e-05	0.00189	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTM1—kidney cancer	1.62e-05	0.00186	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP1A1—kidney cancer	1.56e-05	0.00179	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP1A1—kidney cancer	1.54e-05	0.00177	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.49e-05	0.00171	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—RAF1—kidney cancer	1.39e-05	0.0016	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ACY1—kidney cancer	1.37e-05	0.00157	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TP53—kidney cancer	1.36e-05	0.00157	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.32e-05	0.00152	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—MAPK1—kidney cancer	1.24e-05	0.00143	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PDHB—kidney cancer	1.16e-05	0.00134	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—POMC—kidney cancer	1.16e-05	0.00133	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CCBL1—kidney cancer	1.09e-05	0.00126	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—MAPK1—kidney cancer	9.52e-06	0.00109	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GLIPR1—kidney cancer	9.49e-06	0.00109	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPAT—kidney cancer	9.49e-06	0.00109	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—APRT—kidney cancer	8.82e-06	0.00101	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—FH—kidney cancer	8.82e-06	0.00101	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—RAF1—kidney cancer	8.42e-06	0.000968	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GPC3—kidney cancer	8.3e-06	0.000954	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CA2—kidney cancer	8.07e-06	0.000928	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALAD—kidney cancer	7.87e-06	0.000904	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ST3GAL2—kidney cancer	7.68e-06	0.000882	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALDH1A1—kidney cancer	7.5e-06	0.000863	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—RAF1—kidney cancer	7.46e-06	0.000858	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PGK1—kidney cancer	7.19e-06	0.000827	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC5A3—kidney cancer	7.19e-06	0.000827	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—LDHB—kidney cancer	7.05e-06	0.000811	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CA9—kidney cancer	6.12e-06	0.000703	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CRABP1—kidney cancer	5.2e-06	0.000598	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ITPR2—kidney cancer	4.84e-06	0.000556	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTT1—kidney cancer	4.41e-06	0.000507	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ACHE—kidney cancer	4.41e-06	0.000507	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SCARB1—kidney cancer	4.17e-06	0.00048	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGS1—kidney cancer	4.13e-06	0.000475	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PSMD7—kidney cancer	4.05e-06	0.000466	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—BCHE—kidney cancer	3.84e-06	0.000442	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC5A5—kidney cancer	3.79e-06	0.000436	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC2A1—kidney cancer	3.66e-06	0.000421	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTP1—kidney cancer	3.06e-06	0.000351	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ABCB1—kidney cancer	2.89e-06	0.000333	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTM1—kidney cancer	2.81e-06	0.000323	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP1A1—kidney cancer	2.66e-06	0.000306	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—POMC—kidney cancer	1.99e-06	0.000228	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGS2—kidney cancer	1.58e-06	0.000182	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTEN—kidney cancer	1.38e-06	0.000159	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CA—kidney cancer	9.74e-07	0.000112	CbGpPWpGaD
